Alzheimer’s Prevention Trials—The Future Looks Promising

Alzheimer’s Prevention Trials—The Future Looks Promising

Current prevalence estimates for late-onset Alzheimer’s disease LOAD in the United States (U.S.) is approximately 5.1 million.(1) By 2050 the projected prevalence of LOAD is expected to escalate to 13.8 million and a staggering 106.8 million worldwide.(2,3) Pharmacological treatments for LOAD such as cholinesterase inhibitors and NMDA receptor antagonists may slow its progression or attenuate specific molecular pathomechanisms associated with the disease process, but are not long term solutions or curative. While there is active research for more effective disease-modifying drugs* the lack of any significant breakthroughs in the treatment of the disease has propelled a paradigm shift away from focusing solely on a pharmaceutical solution to an inclusive prevention model that emphasizes risk reduction and ultimately the portentous global burden incurred by the disease.

Several clinical trials have recently explored the potential role of prevention-based interventions for decreasing the risk of late-onset Alzheimer’s disease (LOAD) and vascular dementia. The outcomes are encouraging. Multi-dimensional interventional strategies (implementing multiple treatment and prevention modalities simultaneously) versus mono-therapy (employing only with a single treatment modality e.g. drugs) has yielded promising results in reducing the eventual onset of dementia for aging individuals considered to be at higher risk. These trials highlight the potential effectiveness of preventive approaches for individuals deemed to have a higher risk for vascular dementia and LOAD and for the management of Mild Cognitive Impairment (MCI).**

Protected: PREMIUM CONTENT: Insulin, Brain Function And Alzheimer’s Disease – Is Insulin Resistance To Blame For Alzheimer’s?

Protected: PREMIUM CONTENT: Insulin, Brain Function And Alzheimer’s Disease – Is Insulin Resistance To Blame For Alzheimer’s?

Insulin fulfills an indispensable role in your body’s utilization of blood sugar (glucose). In type 2 diabetes and Metabolic Syndrome, insulin’s function of glucose uptake into the body’s cells is impaired due to a resistance to insulin that develops over time. This insulin resistance pattern which defines the disease process of the above mentioned disorders, is now seen as a link to the degenerative spiral that occurs in Alzheimer’s disease (AD) over and above the role of insulin in glucose metabolism in the brain. Insulin resistance and its role in inflammation, and impaired insulin function in the brain are now understood to be underlying pieces of the Alzheimer’s puzzle.

Pin It on Pinterest

Copy Protected by Chetan's WP-Copyprotect.